MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
May 07, 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 --...
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024 16:10 ET
|
Dyne Therapeutics, Inc.
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
May 02, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294...
Enovis Announces First Quarter 2024 Results
May 02, 2024 06:00 ET
|
Enovis Corporation
Strong start to the year with sales growth of 27% on a reported basis and strong adjusted margin expansionReported first-quarter net loss from continuing operations of $1.32 per share with adjusted...
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
April 30, 2024 09:00 ET
|
Kamari Pharma
NESS ZIONA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic...
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
April 30, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s...
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
April 30, 2024 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister here to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MATEO, Calif. and SINGAPORE,...
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
April 25, 2024 10:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
April 25, 2024 01:30 ET
|
ONWARD Medical NV
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date